[ad_1] <br><div><h2>RedHill Biopharma (<a target="_blank" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rdhl/redhill-biopharma?blueprint=2257369&amp;utm_medium=finance_user&amp;utm_campaign=intro&amp;utm_source=yahoo" rel="nofollow noopener" data-ylk="slk:NASDAQ:RDHL" class="link ">NASDAQ:RDHL</a>) Second Quarter 2022 Outcomes</h2><p><strong>Key Monetary Outcomes</strong></p><ul class="caas-list caas-list-bullet"><li><p>Income: US$18.3m (down 15% from 2Q 2021).</p></li><li><p>Internet loss: US$11.7m (loss narrowed by 60% from 2Q 2021).</p></li><li><p>US$0.21 loss per share (improved from US$0.62 loss in 2Q 2021).</p></li></ul><figure class="caas-figure"><div class="caas-figure-with-pb" style="max-height: 524px"><div><div class="caas-img-container caas-img-loader" style="padding-bottom:64%;"><a target="_blank" class="link" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rdhl/redhill-biopharma/future?blueprint=2257369&amp;amp;utm_medium=finance_user&amp;amp;utm_campaign=infographic&amp;amp;utm_source=yahoo" title="" data-ylk="" rel="noopener"><img class="caas-img caas-lazy" alt="earnings-and-revenue-growth" src="https://s.yimg.com/ny/api/res/1.2/6xpO6B3zyaRQL4yvHL1tiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYxMw--/https://media.zenfs.com/en/simply_wall_st__316/ce8dbc7b3955f35d0ad77b0159285e13"/><noscript><img alt="earnings-and-revenue-growth" src="https://s.yimg.com/ny/api/res/1.2/6xpO6B3zyaRQL4yvHL1tiA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTYxMw--/https://media.zenfs.com/en/simply_wall_st__316/ce8dbc7b3955f35d0ad77b0159285e13" class="caas-img"/></noscript></a></div></div></div><p><figcaption class="caption-collapse">earnings-and-revenue-growth</figcaption></p></figure><p><i>All figures proven within the chart above are for the trailing 12 month (TTM) interval</i></p><p><strong>RedHill Biopharma Revenues and Earnings Miss Expectations</strong></p><p>Income missed analyst estimates by 15%. Earnings per share (EPS) additionally missed analyst estimates by 33%.</p><p>Trying forward, income is forecast to develop 24% p.a. on common through the subsequent 3 years, in comparison with a 3.9% progress forecast for the Prescription drugs trade within the US.</p><p><i><a target="_blank" href="https://simplywall.st/markets/us/healthcare/pharma?blueprint=2257369&amp;utm_medium=finance_user&amp;utm_campaign=industry&amp;utm_source=yahoo" rel="nofollow noopener" data-ylk="slk:Performance of the American Pharmaceuticals industry." class="link ">Performance of the <strong>American Pharmaceuticals industry.</strong></a></i></p><p>The corporate's shares are down 16% from per week in the past.</p><p><strong>Danger Evaluation</strong></p><p>It is best to be taught concerning the <a target="_blank" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-rdhl/redhill-biopharma?blueprint=2257369&amp;utm_medium=finance_user&amp;utm_campaign=conclusion&amp;utm_source=yahoo" rel="nofollow noopener" data-ylk="slk:5 warning signs we've spotted with RedHill Biopharma (including 2 which are a bit unpleasant)" class="link "> <strong> 5 warning signs </strong> we've spotted with RedHill Biopharma (including 2 which are a bit unpleasant)</a>.</p><p><strong>Have suggestions on this text? Involved concerning the content material?</strong> <a target="_blank" href="https://feedback.simplywall.st/article/MjI1NzM2OTowMTI3MDUxZWVmMzQxNzQy" rel="nofollow noopener" data-ylk="slk:Get in touch" class="link "><strong>Get in touch</strong></a><strong> with us straight.</strong><i> Alternatively, e-mail editorial-team (at) simplywallst.com.</i></p><p><i>This text by Merely Wall St is normal in nature. <strong>We offer commentary primarily based on historic knowledge and analyst forecasts solely utilizing an unbiased methodology and our articles are usually not supposed to be monetary recommendation.</strong> It doesn't represent a suggestion to purchase or promote any inventory, and doesn't take account of your targets, or your monetary state of affairs. We goal to convey you long-term centered evaluation pushed by elementary knowledge. Observe that our evaluation could not issue within the newest price-sensitive firm bulletins or qualitative materials. Merely Wall St has no place in any shares talked about.</i></p><p><strong>Be part of A Paid Person Analysis Session</strong><br/>You’ll obtain a <i>US$30 Amazon Reward card</i> for 1 hour of your time whereas serving to us construct higher investing instruments for the person traders like your self. <a target="_blank" href="https://investor-research.typeform.com/to/othMTqFM" rel="nofollow noopener" data-ylk="slk:Sign up here" class="link ">Sign up here</a></p></div> <br>[ad_2] <br><a href="https://news.google.com/__i/rss/rd/articles/CBMiU2h0dHBzOi8vZmluYW5jZS55YWhvby5jb20vbmV3cy9yZWRoaWxsLWJpb3BoYXJtYS1zZWNvbmQtcXVhcnRlci0yMDIyLTEyMzMzNjMzNS5odG1s0gFbaHR0cHM6Ly9maW5hbmNlLnlhaG9vLmNvbS9hbXBodG1sL25ld3MvcmVkaGlsbC1iaW9waGFybWEtc2Vjb25kLXF1YXJ0ZXItMjAyMi0xMjMzMzYzMzUuaHRtbA?oc=5">Source link </a>